SpyGlass Pharma reported a net loss of $19.9 million, or $0.59 per share, for the quarter ended June 30, widening from $8.7 million a year earlier. The deeper loss highlights soaring R&D and administrative costs as the firm funds late‑stage glaucoma trials, testing its $234.2 million cash cushion.
Key Highlights
- EPS $‑0.69 missed consensus $‑0.51, widening loss
- Cash $234.2 million funds operations through 2028
- Phase 3 enrollment on track for 2027; BIM‑DRS first‑in‑human trial slated H2 2026
SpyGlass Pharma posted a net loss of $19.9 million, or $0.59 per share, for the quarter ended June 30, a sharp increase from the $8.7 million loss a year earlier. Earnings per share came in at $‑0.69 versus a consensus estimate of $‑0.51, underscoring the cost pressure from expanding clinical programs. The company’s cash balance of $234.2 million should carry it through 2028, but the widening loss draws attention to the capital intensity of its pipeline.
Investors must gauge whether the cash runway can sustain the upcoming trial milestones.
EPS Miss Deepens Loss
This miss coincides with a rise in research and development expense to $10.9 million, up from $7.3 million a year earlier, as the firm hired additional clinical staff for its Phase 3 registrational trials. General and administrative costs also surged to $11.0 million from $2.0 million, driven by higher professional service fees. The combination of higher spending and a missed earnings target expands the loss, a development that could pressure valuation until data from the trials materialize.
Cash, Costs, and CPT Code Advance
Cash, cash equivalents and short‑term investments stood at $234.2 million, a level the company says will fund its operations through 2028. Operating expenses climbed to $21.967 million, with R&D and admin increases accounting for the bulk of the rise. In May, the AMA approved an add‑on Category III CPT code (+1090T) that pairs with existing Category I codes 66984 and 66991, creating a dedicated reimbursement pathway for the BIM‑IOL system.
The new code could accelerate commercial uptake, yet the company must still navigate the regulatory and manufacturing steps before realizing revenue.
Market Reaction and Short Position
The stock’s short interest sits at 3% of shares outstanding with 7.9 days of average volume to cover, a 14% decline from the prior settlement, indicating a modest short‑selling presence. Sector peers OMER fell 0.5%, while COLL and AMPH rose 2.8% and 1.5% respectively, positioning SpyGlass as a relative outlier amid mixed peer performance. The combination of a widening loss and a solid cash position may keep investors watching for trial data that could shift sentiment.
Upcoming Milestones
The company expects to finish enrollment in its parallel Phase 3 BIM‑IOL registrational trials by 2027, while the first‑in‑human BIM‑DRS study is slated for the second half of 2026. Four‑year efficacy and safety follow‑up for the BIM‑IOL system is due in the fourth quarter of 2026. The next quarterly earnings release will provide an update on cash burn and any early data from the ongoing trials, serving as the immediate catalyst for the stock.
Peers Moving on This News
- Omeros Corp (OMER) down 0.5%
- Collegium Pharmaceutical Inc (COLL) up 2.8%
- Amphastar Pharmaceuticals, Inc (AMPH) up 1.5%
Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...